Background. Dupilumab represents the first approved biological for severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Objective. Aim of this paper is to provide a multicentric real-life study about treatment with dupilumab for CRSwNP with a special focus on blood parameters and IgE, IgG, and IgA. Method. A retrospective data collection was jointly conducted at the Otolaryngology departments of San Camillo Forlanini Hospital and University of Rome “La Sapienza” from December 2020 to January 2023. Results. A total of 130 patients were included in the study. Monitoring our patients for 18 months, we observed a reduction in nasal polyposis and an improvement in symptoms and their impact on quality of life. Regarding blood tests, a transient increase in blood eosinophils was found in most cases. Total IgE showed a gradual decrease in values. IgG and IgA also showed a slight reduction of values, while remaining within normal ranges. Conclusion. To the best of our knowledge, this is the first study to evaluate the impact of dupilumab on several blood parameters in patients receiving treatment for CRswNP. Further studies are needed to confirm our results and to understand the underlying immunological mechanisms.

Dupilumab’s impact on blood parameters in nasal polyposis: 18-month follow-up in real life / Loperfido, Antonella; Ciofalo, Andrea; Cavaliere, Carlo; Begvarfaj, Elona; Cascone, Francesca; Alfonzo, Giacomo; Cadeddu, Rosalba; Millarelli, Stefano; Bellocchi, Gianluca; Greco, Antonio; DE VINCENTIIS, Marco; Masieri, Simonetta. - In: JOURNAL OF IMMUNOLOGY RESEARCH. - ISSN 2314-7156. - 2023:(2023). [10.1155/2023/4027701]

Dupilumab’s impact on blood parameters in nasal polyposis: 18-month follow-up in real life

Andrea Ciofalo
Secondo
;
Carlo Cavaliere
;
Elona Begvarfaj;Francesca Cascone;Giacomo Alfonzo;Rosalba Cadeddu;Antonio Greco;Marco de Vincentiis
Penultimo
;
Simonetta Masieri
Ultimo
2023

Abstract

Background. Dupilumab represents the first approved biological for severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Objective. Aim of this paper is to provide a multicentric real-life study about treatment with dupilumab for CRSwNP with a special focus on blood parameters and IgE, IgG, and IgA. Method. A retrospective data collection was jointly conducted at the Otolaryngology departments of San Camillo Forlanini Hospital and University of Rome “La Sapienza” from December 2020 to January 2023. Results. A total of 130 patients were included in the study. Monitoring our patients for 18 months, we observed a reduction in nasal polyposis and an improvement in symptoms and their impact on quality of life. Regarding blood tests, a transient increase in blood eosinophils was found in most cases. Total IgE showed a gradual decrease in values. IgG and IgA also showed a slight reduction of values, while remaining within normal ranges. Conclusion. To the best of our knowledge, this is the first study to evaluate the impact of dupilumab on several blood parameters in patients receiving treatment for CRswNP. Further studies are needed to confirm our results and to understand the underlying immunological mechanisms.
2023
Dupilumab, nasal polyps, crswnp, monoclonal antibodies
01 Pubblicazione su rivista::01a Articolo in rivista
Dupilumab’s impact on blood parameters in nasal polyposis: 18-month follow-up in real life / Loperfido, Antonella; Ciofalo, Andrea; Cavaliere, Carlo; Begvarfaj, Elona; Cascone, Francesca; Alfonzo, Giacomo; Cadeddu, Rosalba; Millarelli, Stefano; Bellocchi, Gianluca; Greco, Antonio; DE VINCENTIIS, Marco; Masieri, Simonetta. - In: JOURNAL OF IMMUNOLOGY RESEARCH. - ISSN 2314-7156. - 2023:(2023). [10.1155/2023/4027701]
File allegati a questo prodotto
File Dimensione Formato  
Loperfido_Dupilumab’s Impact_2023.pdf

accesso aperto

Note: This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 476.72 kB
Formato Adobe PDF
476.72 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1688464
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact